文献速递淋巴瘤

合并症对老年弥漫大B细胞淋巴瘤患者结局的影响

Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma.
PubMed 文献 · Am J Hematol · 2017-07-19

研究纳入413例在克利夫兰诊所治疗的年龄≥60岁弥漫大B细胞淋巴瘤患者,中位年龄69岁,58%患者IPI评分高,85%患者Charlson合并症指数(CCI)低。高IPI、高CCI、化疗减量、治疗相关不良事件(TAE)和住院是死亡与复发的显著预测因素;多变量分析中高IPI和高CCI为总生存和无进展生存的独立预测因素,联合IPI与CCI的简单模型可区分三个预后风险组。

要点

  • 413例≥60岁DLBCL患者中,58%IPI评分高,85%CCI低,40%需化疗减量,78%达完全缓解。
  • 高IPI、高CCI、化疗减量、TAE和住院均为死亡与复发的显著预测因素。
  • 多变量分析中高IPI和高CCI为总生存及无进展生存的独立预测因素。

核心结论

  • 结果提示将CCI纳入当前预后模型可改善老年DLBCL患者的预后判断,CCI可能是评估老年患者临床试验入组资格的有价值工具。

研究设计与样本

  • 研究为在克利夫兰诊所连续纳入413例年龄≥60岁接受治疗的DLBCL患者。
  • 诊断时中位年龄69岁,58%患者IPI评分高,85%患者CCI低。

主要发现

  • 40%患者在治疗期间需要减量,78%达到完全缓解(CR),70%经历至少一次II-IV级TAE。
  • 高IPI评分、高CCI、化疗减量、TAE和住院是死亡和复发的显著预测因素。
  • 多变量分析中,高IPI和高CCI是总生存和无进展生存的独立预测因素。
  • 结合IPI和CCI的简单模型可可靠区分三个预后不同的风险组。

临床怎么用

  • 作者认为将CCI纳入当前预后模型可改善老年DLBCL患者的预后判断。
  • 作者认为CCI可能是评估老年患者临床试验入组资格的有价值工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

International prognostic index (IPI) has remained the primary prognostic tool in diffuse large B cell lymphoma (DLBCL) for more than 20 years. Even though the disease is more common in older population, the impact of comorbidities, dose reductions, and treatment-related adverse events (TAEs) on the outcome in elderly DLBCL patients has not been well established. We studied 413 consecutive patients aged ≥ 60 years who were treated at the Cleveland Clinic. The median age at diagnosis was 69 years, 58% of patients had high IPI score, and 85% had low Charlson comorbidity index (CCI). Forty percent of patients required dose reductions during treatment, 78% achieved CR, and 70% experienced at least one grade II-IV TAE. High IPI score, high CCI, reduced dose chemotherapy, TAE, and hospitalization were significant predictors of death and relapse. In multivariable analysis, high IPI and CCI were independent predictors of overall and progression free survival. A simple model combining IPI and CCI could reliably distinguish three prognostically separate risk groups. Our results suggest that incorporation of CCI in current prognostic models can improve prognostication of older DLBCL patients and CCI might be a valuable tool in evaluating the eligibility of older patients for clinical trial enrollment.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Saygin C, Jia X, Hill B, et al. Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma. Am J Hematol. 2017. PMID: 28612386. doi:10.1002/ajh.24819

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。